Candel completes Phase 3 enrollment for CAN-2409 in prostate cancer
https://www.biospace.com/article/releases/candel-therapeutics-completes-enrollment-in-phase-3-clinical-trial-of-can-2409-in-combination-with-valacyclovir-for-the-treatment-of-intermediate-high-risk-…